| Trial | GO44479 |
|---|---|
| Cancer Type | Pancreatic Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA |
| Trial | Precision-Panc |
|---|---|
| Cancer Type | Gastrointestinal and Pancreatic Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | Master Protocol Personalising Treatment For Pancreatic Cancer |
| Trial | UCB6114 CRUKD24002 |
|---|---|
| Cancer Type | Pancreatic Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously with i) first-line standard of care nab-paclitaxel and gemcitabine, or ii) in combination with MEK inhibitor maintenance therapy |
 |
Click Here to view Cancer Research UK trial summary |